Name: MERCK & CO. INC. (MRK) Stock
Brand: MERCK & CO. INC.
Rating: 7.5 (3 reviews)

MRK Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Chartmill - Mentions: FCX ALB DECK PCAR ...

Which S&P500 stocks are moving on Tuesday?

2 days ago - By: Chartmill - Mentions: MDT HD NFLX

Which S&P500 stocks have an unusual volume on Tuesday?

3 hours ago - By: Stocktwits - Mentions: UNH BMY NVS

Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices

14 hours ago - By: Benzinga - Mentions: GILD

Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment

14 hours ago - By: Stocktwits - Mentions: GILD

Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study

17 hours ago - By: Zacks Investment Research - Mentions: JNJ UTHR

Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study

21 hours ago - By: Merck & Co., Inc.

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection

21 hours ago - By: Merck & Co., Inc.

European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union

2 days ago - By: Benzinga - Mentions: MU TPL DIA WDC ...

Tech Stocks Drop, Pharma Gains As Sector Rotation Picks Up: What's Moving Markets Tuesday?

2 days ago - By: Chartmill - Mentions: FCX ADM DECK PCAR ...

Uncover the latest developments among S&P500 stocks in today's session.

2 days ago - By: Merck & Co., Inc.

Merck Announces First-Quarter 2026 Dividend

2 days ago - By: Zacks Investment Research - Mentions: JNJ PFE CDTX

J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B

2 days ago - By: Investor's Business Daily - Mentions: LLY

Merck Jumps On A Surprise Win; Why It Still Has A Long Road To Go

2 days ago - By: Chartmill - Mentions: FCX INCY MOH MDT ...

Top S&P500 movers in Tuesday's pre-market session

2 days ago - By: Investor's Business Daily - Mentions: LGND OABI RPRX TVTX ...

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year

2 days ago - By: Merck & Co., Inc.

Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)

3 days ago - By: Zacks Investment Research - Mentions: PFE NVO CDTX

MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026

3 days ago - By: Zacks Investment Research - Mentions: MRNA CDTX SMMT

MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?

3 days ago - By: Chartmill

MERCK & CO. INC. (NYSE:MRK): A Value Investment with Strong Fundamentals

3 days ago - By: Stocktwits - Mentions: CDTX

Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover

4 days ago - By: The Motley Fool - Mentions: SCHD KO CVX COP ...

These 2 Dividend ETFs Are a Retiree's Best Friend

6 days ago - By: Investor's Business Daily - Mentions: RY RY.CA CDTX

Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal

6 days ago - By: Zacks Investment Research

Here's Why Merck (MRK) is a Strong Growth Stock

6 days ago - By: Zacks Investment Research - Mentions: BMY JNJ PFE LLY ...

Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

6 days ago - By: Bloomberg - Mentions: CDTX

Merck to Acquire Cidara Therapeutics in $9.2 Billion Deal

6 days ago - By: Stocktwits - Mentions: CDTX

Merck To Buy Cidara In $9.2B Deal To Strengthen Antiviral Portfolio

6 days ago - By: Merck & Co., Inc.

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

6 days ago - By: Stocktwits - Mentions: CDTX VRNA PFE NVO ...

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium

6 days ago - By: Zacks Investment Research - Mentions: BRK AMAT AU BZH ...

Pulling Back for a Fresh Look at This Recent Pullback

9 days ago - By: Chartmill - Mentions: DVN APP CI ALGN ...

Exploring the top movers within the S&P500 index during today's session.

9 days ago - By: Chartmill - Mentions: DVN APP NKE ALGN ...

What's going on in today's session: S&P500 movers

14 days ago - By: Chartmill

Merck & Co. Inc. (NYSE:MRK) Presents a Compelling Case for Dividend Investors

21 days ago - By: Chartmill

MERCK & CO. INC. (MRK) Stock News